Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
68,000
-200 (-0.29%)
At close: Sep 4, 2026
KRX:185750 Revenue
Chong Kun Dang Pharmaceutical had revenue of 478.47B KRW in the quarter ending June 30, 2026, with 10.03% growth. This brings the company's revenue in the last twelve months to 1.78T, up 7.15% year-over-year. In the year 2025, Chong Kun Dang Pharmaceutical had annual revenue of 1.69T with 6.68% growth.
Revenue (ttm)
1.78T
Revenue Growth
+7.15%
P/S Ratio
0.50
Revenue / Employee
821.58M
Employees
2,190
Market Cap
895.97B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.69T | 105.97B | 6.68% |
| Dec 31, 2024 | 1.59T | -82.97B | -4.97% |
| Dec 31, 2023 | 1.67T | 181.06B | 12.17% |
| Dec 31, 2022 | 1.49T | 144.79B | 10.78% |
| Dec 31, 2021 | 1.34T | 40.55B | 3.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Daewoong | 2.12T |
| GC Biopharma | 1.96T |
| Daewoong Pharmaceutical | 1.64T |
| Dong-A Socio Holdings | 1.52T |
| Boryung | 1.06T |
| Dong-A ST | 860.94B |
| JW Pharmaceutical | 820.86B |
| Ildong Pharmaceutical | 582.33B |